Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 153Lung Neoplasms 73Pancreatic Neoplasms 44Neoplasms 27Neoplasm Metastasis 25Head and Neck Neoplasms 23Brain Neoplasms 21Breast Neoplasms 18Glioblastoma 15Adenocarcinoma of Lung 15Squamous Cell Carcinoma of Head and Neck 14Gliosarcoma 14Adenocarcinoma, Bronchiolo-Alveolar 11Colorectal Neoplasms 10Glioma 9Carcinoma, Squamous Cell 8Carcinoma, Hepatocellular 8Adenocarcinoma 7Rectal Neoplasms 6Prostatic Neoplasms 6Esophageal Neoplasms 6Central Nervous System Neoplasms 6Carcinoma, Renal Cell 6Astrocytoma 6Oligodendroglioma 5Liver Neoplasms 5Colonic Neoplasms 5Carcinoma 5Recurrence 4Ovarian Neoplasms 4

Interventions

Letrozole 1Goserelin 1Erlotinib Hydrochloride 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone-sensitive Metastatic Breast Cancer × Erlotinib Hydrochloride × Clear all
NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
11 enrolled 9 charts
Breast

Hormone-sensitive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡